INVA Q1 2025 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$89M+14.4% YoY

Gross Profit

$80M90.0% margin

Operating Income

-$41M-46.7% margin

Net Income

-$47M-52.6% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

-3.5%

Cash Flow

Operating Cash Flow

$49M

Free Cash Flow

$49M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$607M

Stockholders' Equity

$647M

Cash & Equivalents

$319M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$89M	$77M	+14.4%
Gross Profit	$80M	$67M	+19.9%
Operating Income	-$41M	$26M	-260.5%
Net Income	-$47M	$37M	-227.5%

Revenue Segments

Royalty

$58M65%

Product

$30M34%

License And Other Revenue

$546,0001%